4-1BB based Bispecific ADC

The development of 4-1BB based bispecific ADCs (antibody-drug conjugates) represents an innovative frontier in cancer immunotherapy, combining the specific targeting of bispecific antibodies with the potent cell-killing capabilities of ADCs. These unique therapeutics are designed to engage the 4-1BB receptor, a costimulatory protein expressed on T-cells, while simultaneously delivering a cytotoxic drug to cancer cells. By activating T-cells via 4-1BB engagement and targeting tumor antigens with precision, the 4-1BB based bispecific ADC enhances immune system attack on cancer cells and directly induces tumor cell death. This dual mechanism not only potentiates the antitumor immune response but also reduces the likelihood of tumor resistance. Researchers are actively exploring the full potential of 4-1BB based bispecific ADCs to improve efficacy and safety in treating various types of cancers, paving the way for new, groundbreaking therapies.